Summary
- Current Price
- As of today, AZN price is $155.62, down -1.49% on
- Current Price All-Time High
- AZN price is currently -26.84% below its historical high of $212.71 set on
- Market Cap
- AZN current market cap is $241B, up +4.37% over the past 365 days
- PE Ratio
- AZN current PE ratio is 37.55
- Revenue
- AZN current annual revenue is $58.88B, up +8.84% year-over-year
- Next Earnings
- The next earnings release for AZN is on
Profile
| Metric | Value |
|---|---|
| Full Name | AstraZeneca PLC |
| Ticker | NYSE: AZN |
| Exchange | NYSE |
| Sector | Healthcare |
| Industry | General Drug Manufacturers |
| Country | United Kingdom |
| IPO | |
| Indexes | Not included |
| Website | astrazeneca.com |
| Employees | 96,100 |
Key Metrics
| Metric | Date | Value |
|---|---|---|
| Price | $155.62 | |
| Price, 1D Change | -1.49% | |
| Market Cap | $241B | |
| TTM Dividend Yield | 2.04% | |
| PE Ratio | 37.55 | |
| Beta | 0.87 | |
| Revenue | $59B | |
| Revenue, 1Y Change | +8.84% | |
| EPS | $3.28 | |
| EPS, 1Y Change | +45.72% |
Chart
SUGGESTED SERIES
Events
| Metric | Date | Value |
|---|---|---|
| Next Earnings | ||
| Last Qtr. Earnings | ||
| Last Ann. Earnings | ||
| Last Ex-Dividend | $2.15 | |
| Next Ex-Dividend | $1.06 | |
| Last Split | 1:2 | |
| Next Split | N/A | N/A |
| Last Ticker Change | N/A | N/A |
| Next Ticker Change | N/A | N/A |
🔒 Log In To Unlock Full Data
Estimates
| Metric | Date | Value |
|---|---|---|
| EPS | $3.28 | |
| EPS Estimate | N/A | $7.60 |
| EPS Est. Change | N/A | +131.67% |
| Revenue | $58.88B | |
| Revenue Estimate | N/A | $63.28B |
| Revenue Est. Change | N/A | +7.48% |
| Current Price | $155.62 | |
| Price Target | - | $214.50 |
| Price Tgt. Change | - | +37.84% |
🔒 Log In To Unlock Full Data
EPS
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| $4.13 | $2.25 | -45.42% | |
| $4.56 | $3.28 | -28.05% | |
| $7.60 | N/A | +131.67% | |
| $8.68 | N/A | +164.69% |
Revenue
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| $53.36B | $54.10B | +1.39% | |
| $58.55B | $58.88B | +0.56% | |
| $63.28B | N/A | +7.48% | |
| $66.85B | N/A | +13.55% |
🔒 Log In To Unlock Full Data
Performance
| Metric | Date | Value |
|---|---|---|
| Price, 1Y | +108.63% | |
| Price, 3Y | +124.24% | |
| Market Cap, 1Y | +4.37% | |
| Market Cap, 3Y | +12.19% | |
| Revenue, 1Y | +8.84% | |
| Revenue, 3Y | +32.75% | |
| EPS, 1Y | +45.72% | |
| EPS, 3Y | +211.32% |
🔒 Log In To Unlock Full Data
Technicals
| Metric | Date | Value |
|---|---|---|
| Current Price | $155.62 | |
| SMA 200 | $155.50 | |
| SMA 50 | $177.89 | |
| EMA 200 | $157.80 | |
| EMA 50 | $176.06 | |
| MACD | -$4.61 | |
| Beta | 0.87 | |
| ATR | $5.08 | |
| 14-Day RSI | 30.67 | |
| 10-Day Volatility | 37.18% |
Dividends
| Metric | Date | Value |
|---|---|---|
| Last Paid | $2.15 | |
| Upcoming | $1.06 | |
| Dividend Yield | 2.01% | |
| Total Dividend | $3.13 | |
| Dividends Paid | $4.98B | |
| Payout Ratio | 48.58% |
🔒 Log In To Unlock Full Data
Income & Profitability
| Metric | Date | Value |
|---|---|---|
| Revenue | $58.88B | |
| EPS | $3.28 | |
| Gross Profit | $43.78B | |
| Gross Margin | 74.35% | |
| Operating Income | $13.64B | |
| Operating Margin | 23.16% | |
| Net Income | $10.26B | |
| Net Margin | 17.42% | |
| EBITDA | $19.38B |
🔒 Log In To Unlock Full Data
Financial Health
| Metric | Date | Value |
|---|---|---|
| Debt To Equity | 0.61 | |
| Current Ratio | 0.94 | |
| Quick Ratio | 0.72 | |
| Interest Coverage | - | |
| Piotroski F-Score | - | |
| Altman Z-Score | 3.24 |
Valuations
Balance Sheet
| Metric | Date | Value |
|---|---|---|
| Book Value | $48.67B | |
| Cash & Equivalents | $5.74B | |
| Total Assets | $114.07B | |
| Current Assets | $28.72B | |
| Total Liabilities | $65.30B | |
| Current Liabilities | $30.62B | |
| Total Debt | $29.62B | |
| Short Term Debt | $3.49B | |
| Accounts Payable | $25.28B |
Expenses
| Metric | Date | Value |
|---|---|---|
| Total Expenses | $48.63B | |
| Operating Expenses | $30.14B | |
| Cost Of Goods Sold | $15.10B | |
| SG&A | $0.00 | |
| D&A | $5.75B | |
| Interest Expense | $0.00 | |
| Income Tax | $2.17B |
Cash Flow
| Metric | Date | Value |
|---|---|---|
| CFO | $14.90B | |
| CFI | -$7.11B | |
| CFF | -$7.56B | |
| Capex | $5.92B | |
| Free Cash Flow | $8.98B |
Recent analyst updates
| Metric | Date | Value |
|---|---|---|
| UBS | → | |
| UBS | → | |
| Erste Group | → | |
| TD Cowen | → | |
| Goldman Sachs | ||
| Argus Research | → | |
| BMO Capital | → | |
| Deutsche Bank | → | |
| BMO Capital | → | |
| Deutsche Bank | → |
Analyst sentiment
Institutional ownership
Screeners with AZN
FAQ
- What is the ticker symbol for AstraZeneca PLC?
- The ticker symbol for AstraZeneca PLC is NYSE:AZN
- Does AstraZeneca PLC pay dividends?
- Yes, AstraZeneca PLC pays dividends. The last payment was $2.15, with an ex-dividend date on February 20, 2026
- What sector is AstraZeneca PLC in?
- AstraZeneca PLC is in the Healthcare sector
- What industry is AstraZeneca PLC in?
- AstraZeneca PLC is in the General Drug Manufacturers industry
- What country is AstraZeneca PLC based in?
- AstraZeneca PLC is headquartered in United Kingdom
- When did AstraZeneca PLC go public?
- AstraZeneca PLC initial public offering (IPO) was on May 12, 1993
- Is AstraZeneca PLC in the S&P 500?
- No, AstraZeneca PLC is not included in the S&P 500 index
- Is AstraZeneca PLC in the NASDAQ 100?
- No, AstraZeneca PLC is not included in the NASDAQ 100 index
- Is AstraZeneca PLC in the Dow Jones?
- No, AstraZeneca PLC is not included in the Dow Jones index
- When was AstraZeneca PLC last earnings report?
- AstraZeneca PLC's most recent earnings report was on July 27, 2026
- When does AstraZeneca PLC report earnings?
- The next expected earnings date for AstraZeneca PLC is October 30, 2026
Data Sources & References
- AZN Official Website www.astrazeneca.com
- AZN Profile on Yahoo Finance finance.yahoo.com/quote/AZN
- AZN Profile on NASDAQ.com www.nasdaq.com/market-activity/stocks/azn